MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Milestone Pharmaceuticals Inc (MIST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently undervalued based on analyst ratings and has a strong buy recommendation with a price target of $6, which represents significant upside potential from its pre-market price of $1.93. The technical indicators are neutral, but the low Put-Call Ratios in options data suggest bullish sentiment. While financial performance shows losses, the company has shown improvement in net income, and its product Cardamyst has strong market potential. Given the lack of recent news or significant insider or hedge fund activity, the stock presents a speculative but promising opportunity for long-term growth.
The MACD is positive and contracting, indicating a potential upward trend. RSI is neutral at 44.075, and moving averages are converging, suggesting no strong directional signal. Key support is at $1.9, with resistance at $2.259. The pre-market price of $1.93 is near support, which could provide a favorable entry point.
Analyst coverage initiated with a Strong Buy rating and a $6 price target. The company’s product, Cardamyst, has strong fundamentals for a successful launch, with significant market potential in a 2M patient population.
EPS has declined YoY, and there is no recent news or significant insider or hedge fund activity to act as a catalyst.
In Q4 2025, revenue remained flat YoY at $1.55M. Net income improved by 40.82% YoY but remains negative at -$17.4M. EPS dropped by 15.79% YoY to -$0.16. Gross margin remains strong at 100%.
Raymond James initiated coverage with a Strong Buy rating and a $6 price target, citing strong fundamentals for the company’s lead product, Cardamyst, and significant market potential.
